Agostino Tafuri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1394927/publications.pdf

Version: 2024-02-01

195	11,997	66343	26613
papers	citations	42	107
		h-index	g-index

200	200	200	16594
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Fatigue in newly diagnosed acute myeloid leukaemia: general population comparison and predictive factors. BMJ Supportive and Palliative Care, 2023, 13, e344-e351.	1.6	1
2	Correspondence in reference to the previously published manuscript: Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent Bâ€cell lymphomas. Hematological Oncology, 2023, 41, 571-573.	1.7	0
3	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
4	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi realâ€life experience. Hematological Oncology, 2022, 40, 32-40.	1.7	10
5	COVIDâ€19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British Journal of Haematology, 2022, 196, 559-565.	2.5	20
6	Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group. Annals of Hematology, 2022, 101, 1275-1282.	1.8	2
7	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinicalâ€“Biological Entity?. Journal of Clinical Medicine, 2022, 11, 2596.	2.4	0
8	Gene signature and immune cell profiling by high-dimensional, single-cell analysis in COVID-19 patients, presenting Low T3 syndrome and coexistent hematological malignancies. Journal of Translational Medicine, 2021, 19, 139.	4.4	13
9	SIRT5 Inhibition Induces Brown Fat-Like Phenotype in 3T3-L1 Preadipocytes. Cells, 2021, 10, 1126.	4.1	16
10	Arrhythmias and Cardiogenic Shock: A Rare Disease Presentation of Diffuse Large B-Cell Lymphoma with Cardiac Involvement. Hemato, 2021, 2, 353-357.	0.6	0
11	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
12	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta OncolÃ³gica, 2021, 60, 1520-1526.	1.8	2
13	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
14	Multi-omic approach identifies a transcriptional network coupling innate immune response to proliferation in the blood of COVID-19 cancer patients. Cell Death and Disease, 2021, 12, 1019.	6.3	3
15	Successful Treatment of a Patient With Breast Implantâ€“Associated Anaplastic Large Cell Lymphoma With Local Residual Disease. Annals of Plastic Surgery, 2021, Publish Ahead of Print, .	0.9	5
16	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. Blood, 2021, 138, 1262-1262.	1.4	1
17	Chronic Lymphocytic Leukemia Cells with Mutated Nfkbie Are Positively Selected By Microenvironmental Signals and Display Reduced Sensitivity to Ibrutinib Treatment. Blood, 2021, 138, 248-248.	1.4	1
18	Central nervous system immune reconstitution inflammatory syndrome after autologous stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 268-271.	2.4	3

#	Article	IF	Citations
19	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. Hematological Oncology, 2020, 38, 189-196.	1.7	6
20	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. Blood Cancer Journal, 2020, 10, 96.	6.2	28
21	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
22	SARSâ€CoVâ€2Âin Myelodysplastic Syndromes: A Snapshot From Early Italian Experience. HemaSphere, 2020, 4, e483.	2.7	7
23	Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. In Vivo, 2020, 34, 1407-1413.	1.3	1
24	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. Frontiers in Oncology, 2020, 10, 848.	2.8	5
25	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. International Journal of Hematology, 2020, 112, 141-146.	1.6	2
26	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1113-1118.	2.0	3
27	mTOR Regulation of Metabolism in Hematologic Malignancies. Cells, 2020, 9, 404.	4.1	10
28	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	1.4	2
29	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	1.4	1
30	Metabolic Reprogramming Promotes Myogenesis During Aging. Frontiers in Physiology, 2019, 10, 897.	2.8	19
31	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood, 2019, 134, 935-945.	1.4	148
32	Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNÎ±-Dendritic Cells and Rituximab: a Phase I Clinical Trial. Clinical Cancer Research, 2019, 25, 5231-5241.	7.0	34
33	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2019, 20, 781-794.	10.7	254
34	The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma. Investigational New Drugs, 2019, 37, 548-558.	2.6	10
35	Phosphoproteomic Landscaping Identifies Non-canonical cKIT Signaling in Polycythemia Vera Erythroid Progenitors. Frontiers in Oncology, 2019, 9, 1245.	2.8	6
36	A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review. BMC Cancer, 2019, 19, 50.	2.6	15

#	Article	IF	Citations
37	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood, 2019, 134, 229-229.	1.4	30
38	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	1.4	1
39	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. Leukemia Research, 2018, 69, 18-23.	0.8	2
40	Aggressive lymphomas of the elderly: the <scp>DEVEC</scp> metronomic chemotherapy schedule fits the unfit. British Journal of Haematology, 2018, 183, 819-822.	2.5	7
41	Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series. Kidney and Blood Pressure Research, 2018, 43, 1263-1272.	2.0	17
42	Complete response in advanced breast cancer patient treated with a combination of capecitabine, oral vinorelbine and dasatinib. Experimental Hematology and Oncology, 2018, 7, 2.	5.0	3
43	Biological Aspects of mTOR in Leukemia. International Journal of Molecular Sciences, 2018, 19, 2396.	4.1	24
44	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood, 2018, 132, 767-767.	1.4	21
45	Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget, 2018, 9, 21758-21769.	1.8	3
46	DEVEC metronomic schedule for aggressive B and T-cell lymphomas.. Journal of Clinical Oncology, 2018, 36, 7563-7563.	1.6	0
47	Real Life Use of Bendamustine Plus Rituximab Versus Chlorambucil Plus Rituximab As Front-Line Therapy for Elderly CLL Patients. Retrospective Multicenter Study in the Lazio Region. Blood, 2018, 132, 5550-5550.	1.4	0
48	High Response Rate in Relapsed/Refractory Follicular Lymphoma Following Personalised Immunotherapy with Intranodal IFN-Alfa-Dendritic-Cell and Rituximab. Blood, 2018, 132, 5334-5334.	1.4	0
49	The Calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Experimental Hematology, 2017, 50, 53-76.	0.4	12
50	Hyperspectral Raman imaging of human prostatic cells: An attempt to differentiate normal and malignant cell lines by univariate and multivariate data analysis. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 173, 476-488.	3.9	15
51	Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opinion on Therapeutic Targets, 2017, 21, 705-714.	3.4	25
52	Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia. Advances in Biological Regulation, 2017, 65, 36-58.	2.3	33
53	Energetic mitochondrial failing in vitiligo and possible rescue by cardiolipin. Scientific Reports, 2017, 7, 13663.	3.3	38
54	Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	4.0	13

#	Article	IF	Citations
55	Tramesan, a novel polysaccharide from Trametes versicolor. Structural characterization and biological effects. PLoS ONE, 2017, 12, e0171412.	2.5	20
56	Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells. Oncotarget, 2017, 8, 49451-49469.	1.8	49
57	Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget, 2017, 8, 76525-76557.	1.8	17
58	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017046.	1.3	3
59	Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Current Pharmaceutical Design, 2016, 22, 2358-2388.	1.9	34
60	Targeting Glycolysis and MAPK Pathway: A Combined Pre-Clinical Approach on Acute Myeloid Leukemia. Blood, 2016, 128, 2751-2751.	1.4	0
61	Phosphoproteomic Landscaping Unveils Constitutive cKIT Activation in Human Erythroblasts from Polycythemia Vera (PV) Patients. Blood, 2016, 128, 399-399.	1.4	0
62	Pulmonary Infections in Patients with Myelodysplastic Syndromes Receiving Azacytidine Treatment. Blood, 2016, 128, 5544-5544.	1.4	1
63	The Carboxy-Terminal Domain of Calreticulin (CALR) Exports the Glucocorticoid Receptor (GR) from the Nucleus to the Cytoplasm of Human Erythroid Cells Resetting Their Stress Response. Blood, 2016, 128, 545-545.	1.4	0
64	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. Blood, 2016, 128, 5469-5469.	1.4	0
65	Deferasirox in the Treatment of Iron Overload during Myeloproliferative Neoplasms (MPN). Blood, 2016, 128, 5465-5465.	1.4	1
66	Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias. Blood, 2015, 126, 1925-1929.	1.4	154
67	The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports, 2015, 5, 18137.	3.3	28
68	SP253A NEW STRATEGY TO REMOVE SERUM FREE LIGHT CHAINS(SFLC)IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND ACUTE KIDNEY INJURY (AKI). Nephrology Dialysis Transplantation, 2015, 30, iii462-iii462.	0.7	0
69	Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront. Leukemia and Lymphoma, 2015, 56, 2206-2207.	1.3	6
70	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
71	Chronic phase chronic myeloid leukemia patients who failed interferon alpha and switched to imatinib: Long-term 9-year follow-up of 134 patients. American Journal of Hematology, 2015, 90, E95-E96.	4.1	0
72	An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms. Annals of Hematology, 2015, 94, 771-777.	1.8	25

#	Article	IF	Citations
73	The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling. Experimental Hematology, 2015, 43, 974-985.e1.	0.4	24
74	PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. Oncotarget, 2015, 6, 15008-15021.	1.8	32
75	Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget, 2015, 6, 32089-32103.	1.8	36
76	Diagnostic Value of Minor Salivary Glands Biopsy in Systemic Amyloidosis. Blood, 2015, 126, 5381-5381.	1.4	2
77	The JAK2 V617F Mutation Disrupts the Regulatory Activity Exerted By Calreticulin on the Glucocorticoid Receptor in Erythroid Cells. Blood, 2015, 126, 5216-5216.	1.4	0
78	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821.	1.4	1
79	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. Blood, 2014, 124, 3265-3265.	1.4	0
80	Splenic marginal zone lymphoma in a HIV-1 infected patient: evidence favouring a pathogenetic role of HIV-1 itself in the lymphomagenesis. Infection, 2013, 41, 255-258.	4.7	5
81	New Agents and Approaches for Targeting the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR Cell Survival Pathways. , 2013, , 331-372.		1
82	Transcriptomic and phosphoâ€proteomic analyzes of erythroblasts expanded in vitro from normal donors and from patients with polycythemia vera. American Journal of Hematology, 2013, 88, 723-729.	4.1	32
83	Exclusion Criteria In The Dasision and Enestnd Trials: Which Could Their Impact Be On The Front-Line Treatment Of a â€œReal-lifeâ€•Patient Population With Chronic Myelogenous Leukemia?. Blood, 2013, 122, 4002-4002.	1.4	1
84	Hypoxia-inducible factor-1Î±(Pro-582-Ser) polymorphism prevents iron deprivation in healthy blood donors. Blood Transfusion, 2013, 11, 553-7.	0.4	10
85	Differential Modulation Of cKIT Signaling By CD63 Dictates The Magnitude Of Response To Stem Cell Factor Of Erythroblasts From Adult Blood, Cord Blood and Polycythemia Vera. Blood, 2013, 122, 2850-2850.	1.4	0
86	Modulation Of The Glycolytic Metabolism In Acute Myeloid Leukemia Cells. Blood, 2013, 122, 5045-5045.	1.4	0
87	Proteomic Profile Of CD34+ Cells From Chronic Myeloid Leukemia Patients and From Normal Donors. Blood, 2013, 122, 2712-2712.	1.4	0
88	Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle, 2012, 11, 4447-4461.	2.6	22
89	Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. Blood, 2012, 119, 217-226.	1.4	52
90	Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for â€œverticalâ€•and â€œlateralâ€•combination strategies. Journal of Molecular Medicine, 2012, 90, 1133-1144.	3.9	35

#	Article	IF	Citations
91	MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia, 2012, 26, 778-787.	7.2	126
92	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 2012, 3, 1068-1111.	1.8	279
93	Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.. Oncotarget, 2012, 3, 954-987.	1.8	244
94	The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. Journal of Molecular Medicine, 2012, 90, 667-679.	3.9	54
95	Advances in Targeting Signal Transduction Pathways. Oncotarget, 2012, 3, 1505-1521.	1.8	41
96	Proteomic Signature of CD34+ Cells From Chronic Myeloid Leukemia Patients. Blood, 2012, 120, 3733-3733.	1.4	0
97	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.	1.4	0
98	Targeting Metabolic Pathways for Leukemia Treatment. Blood, 2012, 120, 1371-1371.	1.4	1
99	Incidence of Late Chronic Anemia in Newly Diagnosed Patients with Chronic Myelogenous Leukemia Responsive to Imatinib. Blood, 2012, 120, 3769-3769.	1.4	0
100	Transcriptosome and Phospho-Proteomic Analyses of Erythroblasts Expanded in Vitro From Normal Donors (ND) and From Patients with Polycythemia Vera (PV).. Blood, 2012, 120, 2860-2860.	1.4	0
101	Aberrant Proliferative and Apoptotic Pathways in Acute Lymphoblastic Leukemia (ALL): Molecular Therapies to Overcome Chemo-Resistance. , 2011, , .		1
102	Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging, 2011, 3, 192-222.	3.1	520
103	Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health. Oncotarget, 2011, 2, 135-164.	1.8	509
104	MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients,. Blood, 2011, 118, 3793-3793.	1.4	1
105	Pre Clinical mTOR-Inhibition of Acute Lymphoblastic Leukemia Cells Synergizes with Pro-Apoptotic Target Therapy Through Mcl-1 Down-Regulation,. Blood, 2011, 118, 3581-3581.	1.4	0
106	Clinical Follow-up of Patients with Myeloproliferative Neoplasms Presenting Skin Ulcers During Treatment with Hydroxyurea. Blood, 2011, 118, 5157-5157.	1.4	0
107	Clinical Features of Idiopathic Erythrocytosis Compared to Polycythemia Vera JAK-2 V617F Positive and Negative Patients. Blood, 2011, 118, 5172-5172.	1.4	0
108	Emerging MEK inhibitors. Expert Opinion on Emerging Drugs, 2010, 15, 203-223.	2.4	54

#	Article	IF	Citations
109	Effect of a novel cross-talk mechanism on the RAF/MEK/ERK and PI3K/AKT/mTOR pathways in melanoma: Role of ERK-mediated suppression of PTEN expression.. Journal of Clinical Oncology, 2010, 28, 8574-8574.	1.6	0
110	A Retrospective Epidemiological Analysis of 1572 Cases of Ph1- Myeloprolypherative Neoplasms (MPNs) From 9 Centers In the Latium: Preliminary Results. Blood, 2010, 116, 5065-5065.	1.4	0
111	Bcl-2 and mTOR as Effective Targets for Molecular Therapy of Acute Lymphoblastic Leukemia. Blood, 2010, 116, 3228-3228.	1.4	1
112	Emerging Raf inhibitors. Expert Opinion on Emerging Drugs, 2009, 14, 633-648.	2.4	33
113	Isolated molecular relapse in FIP1L1-PDGFRÎ± hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. Cancer Chemotherapy and Pharmacology, 2009, 63, 1161-1163.	2.3	3
114	Histopathological and molecular features of persistent polyclonal Bâ€¢cell lymphocytosis (PPBL) with progressive splenomegaly. British Journal of Haematology, 2009, 144, 726-731.	2.5	51
115	Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia, 2009, 23, 25-42.	7.2	174
116	Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations. Neoplasia, 2009, 11, 720-W6.	5.3	87
117	Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood, 2009, 113, 1522-1525.	1.4	19
118	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â^' cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	1.4	62
119	Parallel Signaling through PI3K/AKT/mTOR Mediates Resistance to MEK Inhibition in Preclinical Models of Acute Myeloid Leukemia (AML): Synergistic Effects of Combined MEK and mTOR Inhibition.. Blood, 2009, 114, 594-594.	1.4	0
120	Preclinical Study to Sensitize Acute Lymphoblastic Leukemia Primary Cells by Combined mTOR and BCL-2 Inhibition with CCI-779 and ABT-737.. Blood, 2009, 114, 985-985.	1.4	0
121	Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy. Advances in Enzyme Regulation, 2008, 48, 113-135.	2.6	20
122	Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia, 2008, 22, 686-707.	7.2	337
123	Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia, 2008, 22, 708-722.	7.2	222
124	Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. Molecular Pharmacology, 2008, 74, 884-895.	2.3	33
125	Targeting Survival Cascades Induced by Activation of Ras/Raf/MEK/ERK and PI3K/Akt Pathways to Sensitize Cancer Cells to Therapy. , 2008, , 81-114.		2
126	Development of Mek inhibition (MEK-I)-Based Therapeutic Strategies in Acute Myeloid Leukemia (AML). Blood, 2008, 112, 860-860.	1.4	1

#	Article	IF	Citations
127	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways. Blood, 2008, 112, 5161-5161.	1.4	4
128	Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Current Opinion in Investigational Drugs, 2008, 9, 614-30.	2.3	50
129	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2007, 109, 5473-5476.	1.4	46
130	MEK blockade converts AML differentiating response to retinoids into extensive apoptosis. Blood, 2007, 109, 2121-2129.	1.4	38
131	Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood, 2007, 110, 840-846.	1.4	419
132	Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resistance Updates, 2007, 10, 81-100.	14.4	74
133	Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1263-1284.	4.1	1,858
134	Comparative Gene Profiling of Acute Myeloid Leukemia (AML) and Malignant Melanoma (MEL) Cell Lines Exposed to the MEK Inhibitor PD0325901 Reveals Common Effectors of the MEK/ERK Kinase Module.. Blood, 2007, 110, 3470-3470.	1.4	1
135	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. Blood, 2007, 110, 4652-4652.	1.4	0
136	Functional Effects of the Bcl-2/Bcl-xL Inhibitor ABT-737 on Primary Cells from Smoldering Multiple Myeloma.. Blood, 2007, 110, 4782-4782.	1.4	0
137	Protein Expression of p15 and p21 Plays an Unfavorable Prognostic Role in Adult Acute Lymphoblastic Leukemia (ALL) Patients Independently of Their Gene Promoter Methylation Status.. Blood, 2007, 110, 2802-2802.	1.4	2
138	The BCL-2 Antagonist ABT-737 Is Highly Effective on Primary Acute Lymphoblastic Leukemia Cells.. Blood, 2007, 110, 155-155.	1.4	1
139	The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.. Blood, 2007, 110, 3344-3344.	1.4	1
140	Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.. Blood, 2007, 110, 641-641.	1.4	0
141	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood, 2006, 107, 473-479.	1.4	109
142	Increased death receptor resistance and FLIPshort expression in polycythemia vera erythroid precursor cells. Blood, 2006, 107, 3495-3502.	1.4	50
143	Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation. Leukemia Research, 2006, 30, 785-794.	0.8	11
144	Molecular and Functional Effects of the Novel MEK Inhibitor PD0325901 in Preclinical Models of Human Leukemias.. Blood, 2006, 108, 254-254.	1.4	0

#	Article	IF	Citations
145	Protein Expression and Methylation Status of the CKI p21, p15 and p16 in Adult Acute Lymphoblastic Leukemia (ALL) Patients: Prognostic Implications.. Blood, 2006, 108, 1843-1843.	1.4	0
146	Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.. Blood, 2006, 108, 4612-4612.	1.4	0
147	Lympho Node Enlargement in Adultâ€™s Patients Referred to Hematologist: A Frequent Not Classified Clinical Problem. Results from a Retrospective Study.. Blood, 2006, 108, 2486-2486.	1.4	0
148	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood, 2005, 105, 3434-3441.	1.4	178
149	Beyond Single Pathway Inhibition: MEK Inhibitors as a Platform for the Development of Pharmacological Combinations with Synergistic Anti-Leukemic Effects. Current Pharmaceutical Design, 2005, 11, 2779-2795.	1.9	48
150	Diagnostic Approach to CD5+/CD23+ Leukemic Non-Hodgkin Lymphomas Lacking Lymphnode Histopathology.. Blood, 2005, 106, 4690-4690.	1.4	0
151	Apoptosis Susceptibility and Cell-Cycle Distribution in Cells from Myelodysplastic Syndrome Patients: Modulatory In-Vitro Effects of G-CSF and Interferon-Î±. Leukemia and Lymphoma, 2004, 45, 1437-1443.	1.3	2
152	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004, 104, 1995-1999.	1.4	225
153	Breast Cancer Resistance Protein (BCRP) in Adult Acute Lymphoblastic Leukemia Patients.. Blood, 2004, 104, 1897-1897.	1.4	0
154	High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias. Annals of Hematology, 2003, 82, 476-480.	1.8	11
155	Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. Cancer Genetics and Cytogenetics, 2003, 144, 69-72.	1.0	7
156	E2Aâ€“PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features. British Journal of Haematology, 2003, 120, 484-487.	2.5	63
157	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34â˜† human stem cells. British Journal of Haematology, 2003, 123, 720-729.	2.5	12
158	Epidermolysis bullosa and embryonic lethality in mice lacking the multi-PDZ domain protein GRIP1. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6816-6821.	7.1	63
159	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2002, 100, 974-981.	1.4	99
160	Effects of IL-6 Variants in Multiple Myeloma: Growth Inhibition and Induction of Apoptosis in Primary Cells. Leukemia and Lymphoma, 2002, 43, 2369-2375.	1.3	12
161	Partial deletions of long arm of chromosome 6: biologic and clinical implications in adult acute lymphoblastic leukemia. Leukemia, 2002, 16, 2055-2061.	7.2	35
162	Interleukin-11 induces proliferation of human T-cells and its activity is associated with downregulation of p27(kip1). Haematologica, 2002, 87, 373-80.	3.5	14

#	Article	IF	Citations
163	Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. Annals of Hematology, 2001, 80, 614-616.	1.8	16
164	Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. British Journal of Haematology, 2001, 113, 391-399.	2.5	26
165	Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (MylotargTM CMA-676). British Journal of Haematology, 2001, 115, 63-65.	2.5	53
166	ICOS is essential for effective T-helper-cell responses. Nature, 2001, 409, 105-109.	27.8	629
167	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. British Journal of Haematology, 2000, 109, 788-793.	2.5	28
168	Liposomal daunorubicin plus cytosine arabinoside for elderly patients with acute myeloid leukemia The gimema experience. Experimental Hematology, 2000, 28, 1501-1502.	0.4	4
169	Thrombopoietin, Interleukin-11, and Early-Acting Megakaryocyte Growth Factors in Human Myeloid Leukemia Cells. Leukemia and Lymphoma, 2000, 40, 179-190.	1.3	2
170	Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. British Journal of Haematology, 2000, 111, 1065-1070.	2.5	8
171	Flt3L induces the ex-vivo amplification of umbilical cord blood committed progenitors and early stem cells in short-term cultures. British Journal of Haematology, 1999, 106, 133-141.	2.5	21
172	Outpatient management of acute promyelocytic leukemia after consolidation chemotherapy. Leukemia, 1999, 13, 514-517.	7.2	17
173	Cell cycle regulation and induction of apoptosis by IL-6 variants on the multiple myeloma cell line XG-1. Annals of Hematology, 1999, 78, 13-18.	1.8	19
174	Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Experimental Hematology, 1999, 27, 1255-1263.	0.4	16
175	Control of Neonatal Tolerance to Tissue Antigens by Peripheral T Cell Trafficking. , 1998, 282, 1338-1341.		119
176	The Activity of Differentiation Factors Induces Apoptosis in Polyomavirus Large T-Expressing Myoblasts. Molecular Biology of the Cell, 1998, 9, 1449-1463.	2.1	29
177	Impaired fetal T cell development and perinatal lethality in mice lacking the cAMP response element binding protein. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4481-4486.	7.1	287
178	Interleukin-9 in Human Myeloid Leukemia Cells. Leukemia and Lymphoma, 1997, 26, 563-573.	1.3	8
179	Cycling Status of CD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. Blood, 1997, 89, 1189-1196.	1.4	106
180	Interleukin-9 stimulates the proliferation of human myeloid leukemic cells. Blood, 1996, 87, 3852-3859.	1.4	31

#	Article	IF	Citations
181	Interleukin-3 priming in acute myeloid leukaemia patients. British Journal of Haematology, 1995, 91, 234-244.	2.5	5
182	Prognostic value of rhodamine-efflux and MDR-1/P-170 expression in childhood acute leukemia. Leukemia Research, 1995, 19, 927-931.	0.8	32
183	T Cell Awareness of Paternal Alloantigens During Pregnancy. Science, 1995, 270, 630-633.	12.6	524
184	Cell Kinetic, Molecular and Clinical Analysis of Growth Factor Sensitization of Myeloid Leukemia1. , 1994, , 112-136.		0
185	Combination Treatment of Acute Myeloblastic Leukemia with rhGM-CSF and Standard Induction Chemotherapy. Cancer Investigation, 1993, 11, 229-234.	1.3	2
186	Effects of mast cell growth factor on ara-c mediated acute myeloid leukemia cell killing. Stem Cells, 1993, 11, 88-92.	3.2	2
187	High stimulatory activity of dendritic cells from diabetes-prone BioBreeding/Worcester rats exposed to macrophage-derived factors.. Journal of Clinical Investigation, 1993, 91, 2040-2048.	8.2	9
188	Sexual function with and without erythropoietin therapy. International Journal of Artificial Organs, 1992, 15, 440-441.	1.4	0
189	Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: Effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Medical and Pediatric Oncology, 1992, 20, 18-22.	1.0	5
190	Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid). New England Journal of Medicine, 1991, 324, 1385-1393.	27.0	1,226
191	Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 1991, 77, 700-711.	1.4	183
192	DNA and RNA flow cytometric study in multiple myeloma. Clinical correlations. Cancer, 1991, 67, 449-454.	4.1	18
193	Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood, 1991, 77, 700-711.	1.4	1
194	Colony-Stimulating Factors (rhG-CSF, rhGM-CSF, rhIL-3, and BCFG) Recruit Myeloblastic and Lymphoblastic Leukemic Cells and Enhance the Cytotoxic Effects of Cytosine-Arabinoside. Hamatologie Und Bluttransfusion, 1990, 33, 747-762.	0.0	22
195	Sequential Pilot Studies of Intensive Postremission Chemotherapy for Acute Nonlymphocytic Leukemia. Annals of the New York Academy of Sciences, 1987, 511, 436-441.	3.8	0